CAMBRIDGE, Mass., Aug. 30 /CNW/ -- Genzyme Corporation (Nasdaq: GENZ) announced today that it plans to initiate a tender offer to acquire AnorMED, Inc. (Amex: AOM; TSX: AOM) of Vancouver, British Columbia. The tender offer will take the form of an all cash transaction valued at US $8.55 per outstanding share, or approximately $380 million. This offer represents a premium of approximately 70% over AnorMED’s closing price of US$5.02 on the American Stock Exchange on August 29, 2006.
